Welcome to our dedicated page for UNITEDHEALTH GROUP SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UNITEDHEALTH GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UNITEDHEALTH GROUP's regulatory disclosures and financial reporting.
Form 4 overview: UnitedHealth Group Inc. (UNH) reported one insider transaction by Patrick H. Conway, Chief Executive Officer of Optum. On 24 June 2025, Conway acquired 73.058 shares of common stock at a stated price of $0.00. The shares represent dividend equivalents that accrue on previously granted restricted stock units (RSUs); they will vest or be forfeited under the same conditions as the underlying RSUs.
Following the credit, Conway’s total beneficial ownership increased to 10,471.511 shares, held in direct form. No derivative securities were reported in this filing, and there were no dispositions or sales.
Key points for investors:
- The transaction is non-open-market and mechanically linked to existing RSUs, signalling neither an active purchase nor a sale decision.
- The share increase is immaterial—about 0.7% of Conway’s reported holdings and negligible relative to UnitedHealth’s ~930 million shares outstanding.
- No Rule 10b5-1 trading plan was indicated, and there are no signs of strategic shifts, financing activities, or performance commentary in the filing.
Overall, the Form 4 reflects routine compensation-related activity with neutral implications for UnitedHealth shareholders.